Lisinopril全球市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計Lisinopril市場將從 2025 年的 23.1 億美元成長到 2034 年的 36 億美元，2026 年至 2034 年的複合年成長率為 5.04%。

隨著心血管疾病和高血壓盛行率的不斷上升，全球Lisinopril市場正穩步成長。Lisinopril是血管收縮素轉化酵素（ACE）抑制劑，廣泛用於治療高血壓、心臟衰竭和某些腎臟疾病。人們對心血管健康的日益重視以及基本藥物可近性的提高，都極大地推動了這個市場的成長。

推動這一市場發展的主要因素是全球高血壓負擔日益加重，高血壓是最常見的慢性疾病之一。久坐不動的生活方式、不健康的飲食習慣以及不斷上升的壓力水平都會導致心血管疾病的發病率增加。因此，醫療保健機構繼續依賴像Lisinopril這樣有效且價格合理的藥物來控制血壓並降低相關的健康風險。

未來幾年，在人口老化和發展中地區醫療基礎設施不斷完善的推動下，Lisinopril市場預計將保持穩定成長。非專利處方藥的普及以及各國政府旨在改善基本藥物可近性的醫療政策將進一步促進市場擴張。持續關注心血管疾病預防預計將使全球對Lisinopril的需求保持強勁。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球Lisinopril市場：以劑型分類

• 市場分析、洞察與預測
• 藥片
• 液體

第5章：全球Lisinopril市場：依劑量強度分類

• 市場分析、洞察與預測
• 10 mg
• 20 mg
• 25 mg

第6章：全球Lisinopril市場：依病患年齡層別分類

• 市場分析、洞察與預測
• 孩子
• 成人

第7章 全球Lisinopril市場：依應用分類

• 市場分析、洞察與預測
• 高血壓
• 心臟衰竭
• 心臟病發作
• 糖尿病腎臟病
• 其他用途

第8章：全球Lisinopril市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第9章：全球Lisinopril市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • Amneal Pharmaceutical Inc
  • AstraZeneca
  • Apotex Inc
  • Aurobindo Pharma Ltd
  • Bausch Health Companies Inc
  • Cipla Limited
  • Hikma Pharmaceutical PLC
  • Lupin Limited
  • Merck & Co. Inc
  • Pfizer Inc
  • Sun Pharmaceutical Industries Limited

The Lisinopril Market size is expected to reach USD 3.60 Billion in 2034 from USD 2.31 Billion (2025) growing at a CAGR of 5.04% during 2026-2034.

The Global Lisinopril Market is growing steadily due to the rising prevalence of cardiovascular diseases and hypertension worldwide. Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely prescribed to manage high blood pressure, heart failure, and certain kidney conditions. Increasing awareness about cardiovascular health and improved access to essential medications have significantly supported the expansion of this market.

The market is primarily driven by the growing global burden of hypertension, which is one of the most common chronic health conditions. Sedentary lifestyles, unhealthy dietary habits, and increasing stress levels have contributed to higher rates of cardiovascular disorders. As a result, healthcare providers continue to rely on effective and affordable medications like lisinopril to manage blood pressure and reduce related health risks.

In the coming years, the lisinopril market is expected to maintain steady growth due to the increasing aging population and expanding healthcare infrastructure in developing regions. Generic drug availability and government healthcare initiatives aimed at improving access to essential medicines will further support market expansion. With the ongoing focus on cardiovascular disease prevention, demand for lisinopril is expected to remain strong globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Dosage

• Tablet
• Liquid

By Dosage Strength

• 10 Mg
• 20 Mg
• 25 Mg

By Patient Age Group

• Children
• Adults

By Application

• Hypertension
• Heart Failure
• Heart Attack
• Diabetic Kidney Disease
• Other Applications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• AbbVie Inc, Amneal Pharmaceutical Inc, AstraZeneca, Apotex Inc, Aurobindo Pharma Ltd, Bausch Health Companies Inc, Cipla Limited, Hikma Pharmaceutical PLC, Lupin Limited, Merck Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Limited
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LISINOPRIL MARKET: BY DOSAGE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Dosage
• 4.2. Tablet Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LISINOPRIL MARKET: BY DOSAGE STRENGTH 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Dosage Strength
• 5.2. 10 Mg Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. 20 Mg Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. 25 Mg Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LISINOPRIL MARKET: BY PATIENT AGE GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Age Group
• 6.2. Children Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LISINOPRIL MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Hypertension Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Heart Failure Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Heart Attack Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Diabetic Kidney Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LISINOPRIL MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL LISINOPRIL MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Dosage
  • 9.2.2 By Dosage Strength
  • 9.2.3 By Patient Age Group
  • 9.2.4 By Application
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Dosage
  • 9.3.2 By Dosage Strength
  • 9.3.3 By Patient Age Group
  • 9.3.4 By Application
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Dosage
  • 9.4.2 By Dosage Strength
  • 9.4.3 By Patient Age Group
  • 9.4.4 By Application
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Dosage
  • 9.5.2 By Dosage Strength
  • 9.5.3 By Patient Age Group
  • 9.5.4 By Application
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Dosage
  • 9.6.2 By Dosage Strength
  • 9.6.3 By Patient Age Group
  • 9.6.4 By Application
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL LISINOPRIL INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AbbVie Inc
  • 11.2.2 Amneal Pharmaceutical Inc
  • 11.2.3 AstraZeneca
  • 11.2.4 Apotex Inc
  • 11.2.5 Aurobindo Pharma Ltd
  • 11.2.6 Bausch Health Companies Inc
  • 11.2.7 Cipla Limited
  • 11.2.8 Hikma Pharmaceutical PLC
  • 11.2.9 Lupin Limited
  • 11.2.10 Merck & Co. Inc
  • 11.2.11 Pfizer Inc
  • 11.2.12 Sun Pharmaceutical Industries Limited